){kind=logo}
Loeb & Loeb represented Shanghai Haohai Biological Technology Co., Ltd., a biological technology company that carries out the research, development, production and sales of medical devices and drugs, in its going-private transaction of EndyMed Ltd., a medical technology company that designs, develops and commercializes laser-energy based medical aesthetic treatment system.
The acquisition enhances Haohai’s medical aesthetics portfolio by integrating EndyMed’s FDA-cleared radiofrequency systems, positioning the company to serve Asia’s rapidly expanding aesthetics market. The transaction closed in February 2025.
This transaction marks the first Chinese buyer-led going-private transaction of a Tel Aviv Stock Exchange-listed company since 2011, highlighting Loeb’s strength in cross-border public mergers and acquisitions.
The Loeb team was led by Henry Yin, chair of the firm’s Asia M&A and Technology Transactions practices, Capital Markets & Corporate partner Michael Fung and counsel Benjamin Yao and included partner Jeffrey Kung, associate Bowen Yang and paralegal Christine Zhang.
The acquisition enhances Haohai’s medical aesthetics portfolio by integrating EndyMed’s FDA-cleared radiofrequency systems, positioning the company to serve Asia’s rapidly expanding aesthetics market. The transaction closed in February 2025.
This transaction marks the first Chinese buyer-led going-private transaction of a Tel Aviv Stock Exchange-listed company since 2011, highlighting Loeb’s strength in cross-border public mergers and acquisitions.
The Loeb team was led by Henry Yin, chair of the firm’s Asia M&A and Technology Transactions practices, Capital Markets & Corporate partner Michael Fung and counsel Benjamin Yao and included partner Jeffrey Kung, associate Bowen Yang and paralegal Christine Zhang.
-
Chair of Asia M&A and Technology Transactions -
Partner -
Counsel
-
Partner -
Associate